Trial Profile

A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial to Assess Efficacy and Safety of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection Fraction (COMET-HF)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 03 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 Jan 2025 According to a Cytokinetics media release, the company will continue the enrollment in this study throughout 2025, to enable recruitment completion in 2026.
03 Dec 2024 According to a Cytokinetics media release, COMET-HF is being conducted in collaboration with Duke Clinical Research Institute (DCRI), a leading academic research organization, Michael Felker, M.D., M.H.S, is principal investigator of the trial
03 Dec 2024 Status changed from planning to recruiting as per Cytokinetics media release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com